Neuland Labs Q1 FY27: Revenue and PAT Surge Over 100 Percent YoY

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+7.9%Reaction day

₹20023.00

prior close

₹21800.00

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%+7.7% vs market

Pharmaceuticals peers, median of 167sector-0.2%+8.1% vs sector

On the reaction day the stock moved 7.7 pts more than Nifty Smallcap 250 and 8.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-2.8

15m

-2.0

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+7.9+0.2+7.7-0.2+8.1

Next day

+14.4+0.2+14.3+0.3+14.1

+11.1+0.1+11.0+0.6+10.5

+14.8+0.3+14.5+0.6+14.2

+12.4+0.1+12.3+0.5+11.9

+15.4+0.2+15.1+0.9+14.5

+18.1-0.1+18.2-0.2+18.3

15d

+17.0+0.6+16.4-0.2+17.2

+14.6+0.9+13.7+2.3+12.3

+9.6-2.3+11.9+2.4+7.2

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Neuland Labs Q1 FY27 (Jun 30 2026) consolidated revenue at Rs. 64,157.71 lakhs vs Rs. 29,275.27 lakhs YoY. PAT at Rs. 14,767.31 lakhs vs Rs. 1,390 lakhs YoY. EPS Rs. 115.10 vs Rs. 10.83. Board approved Rs. 40 crore corporate guarantee for Gland Pharma loan licence, and Rs. 39.8 crore capacity addition at Unit 1 Bonthapally. Announced strategic CDMO partnership with Gland Pharma for sterile API manufacturing.

Likely market impact

Strong earnings beat with over 100 percent YoY revenue and PAT growth. Capacity expansion and Gland Pharma deal signal growth focus.